Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.InteKrin Therapeutics has reported positive data from a Phase IIa study with INT131, a non-TZD selective peroxisome proliferator-activated receptor modulator, in patients with Type 2 diabetes mellitus.
Subscribe to our email newsletter
In a placebo-controlled, double-blind, four-week Phase IIa study, INT131 administration demonstrated a significant improvement in fasting plasma glucose compared to baseline and placebo at doses of 1mg and 10mg daily, in subjects with Type 2 diabetes mellitus (T2DM) on no drug therapy.
The changes in fasting plasma glucose were accompanied by significant improvements in insulin resistance and an increase in adiponectin, a key biomarker of PPAR-gamma mediated efficacy. INT131 was safe and well tolerated, without evidence of the recognized side effects of the full agonist TZDs at a dose that provides glycemic improvement as good as or better than the highest approved doses of Actos and Avandia.
InteKrin has also initiated a 360-patient, 24-week placebo-controlled Phase IIb study with a 45mg Actos comparator arm in February 2008 and expects results to be completed in the second half of 2009.
Alex DePaoli, chief medical officer of InteKrin, said: “This Phase IIa data demonstrate that it may be possible to achieve significant glucose lowering without recognized TZD adverse effects, such as edema and weight gain, which is a genuine breakthrough for this target.”